TMED1

Across TCGA pan-cancer cohorts, TMED1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TMED1 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TMED1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TMED1 expression acts as an unfavorable survival marker.

PDAC, HNSC, and LUAD are the cancer types where TMED1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.427	0.636	<.001	72	view →
HNSC	OS	Quartile	IV	0.539	1.000	.001	35	view →
LUAD	OS	Quartile	II,III,IV	0.266	0.700	.011	4	view →
LSCC	DFS	Median	All	0.913	0.963	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TMED1–PDAC (OS)

Open the PDAC breakdown →